Clinical Trial Update: Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 monotherapy trial of tovorafenib (DAY101) in melanoma and other solid tumors was terminated, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Urothelial Carcinoma
• Colorectal Cancer
• Melanoma
• Non-small Cell Lung Cancer
• Pancreatic Acinar Cell Carcinoma
• Papillary Thyroid Carcinoma
• Pilocytic Astrocytoma
• Spitzoid Melanoma

Drugs mentioned

• DAY101 (tovorafenib)

Snippet

Sponsor: Day One Biopharmaceuticals, Inc. | Conditions: Melanoma, Solid Tumor | Phase 2 | Status: TERMINATED | Results posted: 2025-10-02